- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06877793
Real-time diagnose van levensbedreigende necrotiserende zacht weefselinfecties (NSTI) met behulp van indocyanine groene (ICG) kinetische modellering
Necrotizing soft-tissue infections (NSTIs, a.k.a. "necrotizing fasciitis" or "flesh-eating bacteria") are aggressive infections that can progress rapidly from mild symptoms to sepsis, multi-organ failure, and death. NSTI cases present with non-specific clinical, imaging, and laboratory findings, and standard-of-care techniques for NSTI diagnosis lack sensitivity and specificity, resulting in frequent misdiagnosis and delayed care, which is the single most important predictor of survival. Consequently, the cumulative mortality rate for patients with NSTIs is 20- 30%; a dire need exists for more accurate and rapid detection of NSTIs. Fluorescence-guided surgery is a nascent technology seeking to improve the recognition of anatomical structures and disease processes using fluorescent probes (fluorophores). Indocyanine green (ICG) is an FDA-approved, near-infrared fluorophore with a >60-year safety record for vascular perfusion assessment. A distinguishing histological feature of NSTIs is prominent blood vessel thrombosis in affected tissues. Leveraging these pro-thrombotic effects, our study group has demonstrated in a first-in-human study (NCT04839302) that intravenous administration of ICG and immediate fluorescence imaging reveals prominent signal deficits in NSTI-positive tissues that differentiate significantly with increased signal seen with more common-and less virulent-infections such as cellulitis. We seek now to evaluate this imaging technique on a broader scale and determine if our findings are consistent for patients affected by NSTI-causing pathogens that are not endemic to our region. This prospective, observational, multicenter clinical study will involve video-rate ICG fluorescence imaging of patients suspected of having NSTIs who present to eight tertiary, Level 1 medical centers across the United States (Aim 1). Using dynamic contrast-enhanced fluorescence imaging (DCE-FI), time profiles of ICG fluorescence intensity from different tissue pixels/regions will be extracted and parameterized to extract first-pass kinetic features. These DCE-FI features, which characterize tissue perfusion, will be evaluated alone and in combination with anonymized electronic medical record data to create a DCE-FI-based clinical decision tool and a machine- learning-based fusion (DCE FI+lab/imaging data) tool; these will be compared to identify the most accurate means of diagnosing NSTIs (Aim 2). The best-performing tool will then be evaluated-compared to current diagnostic tests-in a prospective observational clinical study of patients presenting to tertiary emergency departments with findings concerning for NSTIs (Aim 3). Based on our human study, fluorescence imaging will not delay current standard of care. To ensure data fidelity, all sites will use similar: 1) commercial fluorescence imaging systems and accessories; and 2) validated commercial fluorescence reference phantoms. Based on our early results, we have strong confidence that following rigorous testing, ICG DCE-FI will lead to an entirely new methodology for rapid identification of patients with NSTIs, which will ultimately reduce patient morbidity and improve survival.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Eric R Henderson, MD
- Telefoonnummer: 603-650-5133
- E-mail: Eric.R.Henderson@hitchcock.org
Studie Contact Back-up
- Naam: Morgan T Mazanec, MPH
- Telefoonnummer: 603-308-9233
- E-mail: Morgan.T.Mazanec@Hitchcock.ORG
Studie Locaties
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- University of California, Los Angeles
-
Hoofdonderzoeker:
- Christopher Lee, MD
-
Contact:
- Christopher Lee, MD
- Telefoonnummer: 310-319-1234
- E-mail: ChristopherLee@mednet.ucla.edu
-
Onderonderzoeker:
- Nicholas Bernthal, MD
-
Stanford, California, Verenigde Staten, 94305
- Werving
- Stanford University
-
Hoofdonderzoeker:
- Joseph Forrester, MD
-
Contact:
- Joseph Forrester, MD
- E-mail: jdf1@stanford.edu
-
Onderonderzoeker:
- Ariel Knight, MD
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University/Grady Memorial Hospital
-
Contact:
- Morgan Fuller
- Telefoonnummer: (404) 251-8953
- E-mail: jaimo.ahn@emory.edu
-
Hoofdonderzoeker:
- Jaimo Ahn, MD, PhD
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48104
- Werving
- University of Michigan
-
Contact:
- Molly Hunter, MD
- E-mail: huntmary@med.umich.edu
-
Hoofdonderzoeker:
- Molly Hunter, MD
-
Hoofdonderzoeker:
- Raymond Jean, MD
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten, 03756
- Werving
- Dartmouth-Hitchcock Medical Center
-
Contact:
- Eric R Henderson, MD
- Telefoonnummer: 603-650-5133
- E-mail: Eric.R.Henderson@hitchcock.org
-
Onderonderzoeker:
- Jonathan Elliot, PhD
-
Onderonderzoeker:
- Samuel S Streeter, PhD
-
Onderonderzoeker:
- Macgregor Montano, PharmD
-
Onderonderzoeker:
- Scott Rodi, MD
-
Hoofdonderzoeker:
- Eric R Henderson, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- University of Pennsylvania
-
Contact:
- Niels Martin, MD, PhD
- E-mail: Niels.Martin@pennmedicine.upenn.edu
-
Hoofdonderzoeker:
- Niels Martin, MD, PhD
-
Onderonderzoeker:
- Sunil Singhal, MD, PhD
-
Onderonderzoeker:
- Jane Keating, MD
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- Werving
- University of Pittsburgh Medical Center
-
Contact:
- Kurt Weiss, MD
- Telefoonnummer: (412) 802-4137
- E-mail: weiskr@UPMC.EDU
-
Hoofdonderzoeker:
- Kurt Weiss, MD
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37235
- Werving
- Vanderbilt University
-
Contact:
- Jonathan Schoenecker, MD, PhD
- Telefoonnummer: (615) 936-3391
- E-mail: jon.schoenecker@vumc.org
-
Hoofdonderzoeker:
- Jonathan Schoenecker, MD, PhD
-
Onderonderzoeker:
- William Obremskey, MD
-
Onderonderzoeker:
- Eben Rosenthal, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Patients presenting to the ED or clinic who are considered at intermediate- or high-risk for NSTI.
Beschrijving
Inclusion Criteria:
- Age ≥18 years.
- Clinical suspicion of NSTI based on the local standard of care warranting:
- Hospital admission for observation due to suspected NSTI; and/or
- Soft tissue biopsy to rule in/out suspected NSTI; and/or
- Surgical debridement for suspected NSTI; and/or
- Specific institutional threshold criteria for triggering NSTI work-up; and
- Ability to give written informed consent.
Exclusion Criteria:
- History of allergy to ICG and/or iodine.
- Pregnant women or nursing mothers.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Determine if tissue perfusion, determined by first-pass ICG fluorescence kinetics, is reliably reduced in the setting of a necrotizing infection compared to a non-necrotizing infection.
Tijdsspanne: From enrollment to the end of fluorescence imaging (about 1 day)
|
We will evaluate first-pass fluorescence signal intensity changes from indocyanine green (ICG), a vascular perfusion fluorophore, in the setting of severe soft-tissue infections to determine if ICG fluorescence may be an accurate and reliable diagnostic test for differentiating life-threatening necrotizing infections from non-life-threatening non-necrotizing infections. |
From enrollment to the end of fluorescence imaging (about 1 day)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Determine if first-pass ICG fluorescence kinetics in patients with necrotizing infections vary based on the causative bacterial species.
Tijdsspanne: From enrollment to the end of imaging and lab results (about 30 days)
|
In patients who had a documented necrotizing soft-tissue infection, we will compare first-pass fluorescence signal intensity changes from ICG based on the predominant causative bacterial species isolated from a patient's infection to determine if ICG signal changes vary by species. |
From enrollment to the end of imaging and lab results (about 30 days)
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 02002719
- 1R01AI184513-01 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Data will only be shared in aggregate.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .